| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EHAB from our risk checks.
Enhabit, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.00 |
| 52 Week High | US$14.59 |
| 52 Week Low | US$7.12 |
| Beta | 0 |
| 1 Month Change | -11.59% |
| 3 Month Change | 14.50% |
| 1 Year Change | -33.97% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.00% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For Enhabit, Inc. (NYSE:EHAB) Suggests It's 42% Undervalued
May 10
Here's What Analysts Are Forecasting For Enhabit, Inc. (NYSE:EHAB) After Its Annual Results
Mar 09The Market Doesn't Like What It Sees From Enhabit, Inc.'s (NYSE:EHAB) Revenues Yet
Mar 05Enhabit (NYSE:EHAB) Could Be Struggling To Allocate Capital
Feb 09A Look At The Intrinsic Value Of Enhabit, Inc. (NYSE:EHAB)
Oct 04Enhabit: 40% Slump In Pre-Tax Earnings, Payer Headwinds Remain In Situ, Reiterate Hold
Aug 18Enhabit: Difficult To Justify At 20x Earnings, Reiterate Hold
Jun 07An Intrinsic Calculation For Enhabit, Inc. (NYSE:EHAB) Suggests It's 24% Undervalued
May 31Enhabit beats Q4 top and bottom line estimates; initiates FY23 outlook
Feb 15Enhabit: Difficult Time Ahead According To Market Generated Data (Technical Analysis)
Jan 29Enhabit, Inc.'s (NYSE:EHAB) Intrinsic Value Is Potentially 91% Above Its Share Price
Jan 19Enhabit, Inc.'s (NYSE:EHAB) Shares Lagging The Market But So Is The Business
Dec 07Jana Partners adds stakes in Momentive, Freshpet, Enhabit in Q3, exits Conagra
Nov 14Enhabit acquires Texas-based Caring Hearts Hospice, expands national footprint
Oct 03Enhabit initiated Neutral at Citi on near-term concerns
Aug 19Enhabit Home Health & Hospice falls 13% after Non-GAAP EPS, revenue miss
Aug 01Enhabit: A Chip Off The Old Stock
Jul 18Shareholder Returns
| EHAB | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -1.0% | 0.6% | -0.6% |
| 1Y | -34.0% | 1.6% | 22.4% |
Return vs Industry: EHAB underperformed the US Healthcare industry which returned 1.6% over the past year.
Return vs Market: EHAB underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| EHAB volatility | |
|---|---|
| EHAB Average Weekly Movement | 9.8% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: EHAB's share price has been volatile over the past 3 months.
Volatility Over Time: EHAB's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 10,800 | Barb Jacobsmeyer | www.ehab.com |
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer’s disease, low vision, spinal stenosis, Parkinson’s disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families.
Enhabit, Inc. Fundamentals Summary
| EHAB fundamental statistics | |
|---|---|
| Market cap | US$447.39m |
| Earnings (TTM) | -US$83.00m |
| Revenue (TTM) | US$1.04b |
0.4x
P/S Ratio-5.4x
P/E RatioIs EHAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EHAB income statement (TTM) | |
|---|---|
| Revenue | US$1.04b |
| Cost of Revenue | US$537.20m |
| Gross Profit | US$506.40m |
| Other Expenses | US$589.40m |
| Earnings | -US$83.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.65 |
| Gross Margin | 48.52% |
| Net Profit Margin | -7.95% |
| Debt/Equity Ratio | 76.9% |
How did EHAB perform over the long term?
See historical performance and comparison